The Zhitong Finance App learned that Gilead Sciences (GILD.US) said on Thursday that it will purchase PepStar Therapeutics' oral inflammation drug program with a cash advance payment of 1.275 billion US dollars, which includes an experimental treatment for intestinal diseases. The deal comes after Gilead's experimental oral drug emvistegrast for chronic intestinal diseases announced positive interim results on Monday to add an inflammatory bowel disease (IBD) drug candidate to its product portfolio. Gilead said it believes HCXT-2001 has the potential to be developed alone or jointly with other projects in the pipeline.
Zhitongcaijing · 3d ago
Share
Listen to the news
The Zhitong Finance App learned that Gilead Sciences (GILD.US) said on Thursday that it will purchase PepStar Therapeutics' oral inflammation drug program with a cash advance payment of 1.275 billion US dollars, which includes an experimental treatment for intestinal diseases. The deal comes after Gilead's experimental oral drug emvistegrast for chronic intestinal diseases announced positive interim results on Monday to add an inflammatory bowel disease (IBD) drug candidate to its product portfolio. Gilead said it believes HCXT-2001 has the potential to be developed alone or jointly with other projects in the pipeline.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending